CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-31 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Grant or award · Employee stock option (right to buy) | +65,000 | 65,000 | ||
| 2024-01-31 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Grant or award | +25,000 | 81,034 | ||
| 2024-01-31 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Grant or award · Employee stock option (right to buy) | +65,000 | 65,000 | ||
| 2024-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award | +25,000 | 103,698 | ||
| 2024-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +65,000 | 65,000 | ||
| 2024-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award | +25,000 | 60,248 | ||
| 2024-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award · Employee stock option (right to buy) | +91,000 | 91,000 | ||
| 2024-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award | +25,000 | 74,721 | ||
| 2024-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +65,000 | 65,000 | ||
| 2024-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award | +12,500 | 53,837 | ||
| 2024-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award | +1,000 | 54,837 | ||
| 2024-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award · Employee stock option (right to buy) | +25,000 | 25,000 | ||
| 2024-01-23 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale | −2,062 | $8.96 | $18K | 56,034 |
| 2024-01-23 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale | −2,062 | $8.96 | $18K | 60,484 |
| 2024-01-23 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale | −7,873 | $8.96 | $71K | 234,722 |
| 2024-01-23 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −853 | $9.07 | $8K | 49,721 |
| 2024-01-23 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −1,559 | $9.07 | $14K | 78,698 |
| 2024-01-23 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −910 | $9.07 | $8K | 41,337 |
| 2024-01-04 | Inrig Jula Chief Medical Officer | Sale | −440 | $9.17 | $4K | 35,248 |
| 2024-01-03 | Inrig Jula Chief Medical Officer | Sale | −2,069 | $9.48 | $20K | 35,688 |
Page 25 of 51 · 1,020 trades